| Name | Title | Contact Details |
|---|
With a history of over 25 years, Ceto has forged enduring partnerships with over 2,000 regional and community banks and credit unions nationwide, igniting their profitability and growth. Our unwavering commitment lies in empowering financial institutions with cutting-edge intelligence and transformative solutions, elevating shareholder value, and fostering thriving, prosperous communities. Discover more at ceto.com or dial 866.227.1361 to embark on a transformative journey.
Bank of George emerged with a new brand celebrating our technological advancements in the digital space – GBank! We are proud of our improved digital banking and mobile apps for both your personal and business accounts. With increased functionality and efficiency, we know you will love the new GBank. And as tech advances, so will we. We will never lose sight of the core values that have made us your chosen community bank as we grow. Our goal is to give our clients the highest level of service and care at all times. When they look back and assess their relationship with our institution, the total of all the interactions along their banking journey with GBank equals Your Best Banking Experience Ever!® But it doesnt stop there. Our goal is always to give our colleagues that same level of service and care.
LEAD3R is not your typical executive search firm; we help you create a winning formula that unlocks potential at every level of your leadership team, through recruitment, coaching, and advisory services. We are your strategic partner in ensuring your organization flourishes at every level, driving long-term success through the ever-evolving business environment.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.